𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model

✍ Scribed by Roque Diaz; Paul A Nguewa; Ricardo Parrondo; Carlos Perez-Stable; Irene Manrique; Miriam Redrado; Raul Catena; Maria Collantes; Ivan Peñuelas; Juan Antonio Díaz-González; Alfonso Calvo

Book ID
115010009
Publisher
BioMed Central
Year
2010
Tongue
English
Weight
1019 KB
Volume
10
Category
Article
ISSN
1471-2407

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The dual EGFR/HER-2 tyrosine kinase inhi
The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38
✍ Melissa J. LaBonte; Philipp C. Manegold; Peter M. Wilson; Will Fazzone; Stan G. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 482 KB

## Abstract Members of the human epidermal receptor (HER) family are frequently associated with aggressive disease and poor prognosis in multiple malignancies. Lapatinib is a dual tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) and HER‐2. This study evaluated the the